You are here:

Methylphenidate OROS (Concerta®)

Advice

Recommended for restricted use within the NHS in Scotland.

REASONS FOR ADVICE

Treatment with methylphenidate should be part of a comprehensive treatment programme for attention-deficit hyperactivity disorder (ADHD) when remedial measures alone prove insufficient (under specialist supervision). Because of its substantially greater costs, methylphenidate OROS should be restricted to second line therapy and used only in exceptional circumstances where the supervising clinician has clear evidence of compliance problems. As for other methylphenidate preparations, initiation should be on the recommendation of a specialist in childhood behaviour disorders.

Drug Details

Drug Name: Methylphenidate OROS (Concerta®)
SMC Drug ID: 04/02
Manufacturer: Janssen-Cilag Ltd
Indication: Attention deficit hyperactivity disorder
BNF Category:
Sub Category: 4.4 CNS stimulants and drugs used for attention deficit hyperactivity disorder
Submission Type: Full submission
Status: Superseded
Date Advice Published: 5 July 2002

Back